Table 1.
Studies included in the meta-analysis and characteristics of patients
| Study | Year | Country | BCLC stage | Therapy | Age (years) | Sex (M/F) | No of pts | CR | PR | SD | PD | 1-year OS | 2-year OS | 3-year OS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zheng et al. (13) | 2018 | China | A–B | TACE+MWA | 53.3±8.2 | 79/13 | 92 | 54 | 12 | 9 | 17 | 79 | 55 | 30 |
| TACE | 54.6±10.5 | 143/23 | 166 | 21 | 49 | 22 | 74 | 98 | 67 | 19 | ||||
|
| ||||||||||||||
| An et al. (23) | 2018 | China | A | TACE+MWA | 55 (47–65) | 25/12 | 37 | 11 | 18 | 7 | 1 | 23 | 10 | NA |
| TACE | 56 (49–67) | 22/13 | 35 | 5 | 17 | 10 | 3 | 12 | 3 | NA | ||||
|
| ||||||||||||||
| Zhang et al. (24) | 2017 | China | A–B | TACE+MWA | 55.6±4.6 | 19/11 | 30 | 10 | 12 | 7 | 1 | 24 | 19 | NA |
| TACE | 55.9±4.2 | 18/12 | 30 | 2 | 10 | 12 | 6 | 18 | 12 | NA | ||||
|
| ||||||||||||||
| Huo et al. (25) | 2017 | China | B | TACE+MWA | 58.1±7.8 | 32/4 | 36 | 20 | 10 | 2 | 4 | 29 | 11 | NA |
| TACE | 56.4±7.6 | 29/3 | 32 | 8 | 8 | 4 | 12 | 18 | 5 | NA | ||||
|
| ||||||||||||||
| Dong et al. (31) | 2017 | China | B | TACE+MWA | 54.9±12.3 | 28/3 | 31 | 18 | 8 | 4 | 1 | 30 | 25 | NA |
| TACE | 59.8±8.9 | 27/4 | 31 | 1 | 7 | 11 | 12 | 19 | 15 | NA | ||||
|
| ||||||||||||||
| An et al. (26) | 2017 | China | A | TACE+MWA | 51.3±2.9 | 40/9 | 49 | 10 | 25 | NA | NA | 29 | 23 | NA |
| TACE | 50.3±2.6 | 39/10 | 49 | 6 | 15 | NA | NA | 18 | 13 | NA | ||||
|
| ||||||||||||||
| Zhou et al. (20) | 2016 | China | B | TACE+MWA | 52.3±4.2 | 29/25 | 54 | 16 | 32 | 4 | 2 | 51 | 42 | 36 |
| TACE | 50.5±3.1 | 32/22 | 54 | 10 | 12 | 17 | 15 | 38 | 28 | 21 | ||||
|
| ||||||||||||||
| Yan et al. (21) | 2016 | China | A–B | TACE+MWA | 61.4±4.2 | 27/14 | 41 | NA | NA | NA | NA | 29 | 21 | 13 |
| TACE | 58.7±3.4 | 19/13 | 32 | NA | NA | NA | NA | 19 | 12 | 6 | ||||
|
| ||||||||||||||
| Liu et al. (29) | 2016 | China | B | TACE+MWA | 58.7±7.1 | 43/19 | 62 | 19 | 37 | 4 | 2 | 59 | 48 | NA |
| TACE | 58.3±7.3 | 45/17 | 62 | 11 | 14 | 21 | 16 | 43 | 32 | NA | ||||
|
| ||||||||||||||
| He et al. (28) | 2016 | China | A–B | TACE+MWA | 53 (32–73) | 36/6 | 32 | 6 | 12 | 5 | 5 | 26 | 18 | NA |
| TACE | 52 (40–69) | 22/6 | 28 | 2 | 12 | 6 | 8 | 18 | 12 | NA | ||||
|
| ||||||||||||||
| Guo et al. (19) | 2015 | China | B | TACE+MWA | 48 (35–67) | 26/16 | 42 | 19 | 11 | 7 | 5 | 31 | 14 | NA |
| TACE | 50 (39–73) | 24/18 | 42 | 10 | 8 | 9 | 15 | 24 | 4 | NA | ||||
|
| ||||||||||||||
| Chang et al. (18) | 2015 | China | B | TACE+MWA | 59.4±10.5 | 30/3 | 33 | 18 | 14 | 0 | 1 | 21 | 5 | 1 |
| TACE | 57.3±10.9 | 28/6 | 34 | 7 | 15 | 9 | 3 | 9 | 2 | 0 | ||||
|
| ||||||||||||||
| Zhao et al. (22) | 2009 | China | A–B | TACE+MWA | 51 (20–79) | 18/9 | 28 | 5 | 14 | NA | NA | 26 | 17 | NA |
| TACE | 52 (27–80) | 46/9 | 55 | 3 | 19 | NA | NA | 46 | 21 | NA | ||||
|
| ||||||||||||||
| Liu et al. (29) | 2018 | China | B | TACE+MWA | 55.7±5.1 | 30/23 | 53 | 11 | 14 | 16 | 12 | NA | NA | NA |
| TACE | 55.7±5.1 | 26/27 | 53 | 5 | 10 | 15 | 23 | NA | NA | NA | ||||
|
| ||||||||||||||
| Zhang et al. (15) | 2013 | China | B | TACE+MWA | 52.2±2.3 | 20/2 | 22 | 1 | 6 | 1 | 14 | NA | NA | NA |
| TACE | 48.3±2.2 | 18/0 | 18 | 0 | 3 | 0 | 15 | NA | NA | NA | ||||
|
| ||||||||||||||
| Shu et al. (17) | 2014 | China | B | TACE+MWA | 61.2±11.4 | 15/9 | 24 | 7 | 10 | 4 | 3 | 23 | 20 | 16 |
| TACE | 60.3±8.9 | 15/11 | 26 | 2 | 8 | 10 | 6 | 18 | 13 | 9 | ||||
|
| ||||||||||||||
| Hu et al. (16) | 2013 | China | B | TACE+MWA | 43.2±5.1 | 23/25 | 48 | 13 | 20 | 10 | 5 | NA | NA | NA |
| TACE | 44.3±4.9 | 22/26 | 48 | 8 | 15 | 14 | 9 | NA | NA | NA | ||||
|
| ||||||||||||||
| Tao et al. (32) | 2016 | China | A–B | TACE+MWA | 46.5±6.5 | 15/10 | 25 | 8 | 10 | 5 | 2 | 23 | 20 | 16 |
| TACE | 46.7±6.5 | 17/8 | 25 | 2 | 7 | 8 | 8 | 17 | 13 | 9 | ||||
|
| ||||||||||||||
| Huang et al. (30) | 2015 | China | A | TACE+MWA | 62.3±3.5 | 20/4 | 24 | NA | NA | NA | NA | 11 | NA | 5 |
| TACE | 61.2±3.1 | 18/6 | 24 | NA | NA | NA | NA | 10 | NA | 3 | ||||
|
| ||||||||||||||
| Xu et al. (14) | 2013 | China | B | TACE+MWA | 54.5±13.0 | 48/8 | 56 | NA | NA | NA | NA | 49 | NA | 28 |
| TACE | 53.1±14.8 | 73/7 | 80 | NA | NA | NA | NA | 50 | NA | 14 | ||||
Age is presented as mean ± standard deviation or median (range).
BCLC, Barcelona Clinic Liver Cancer staging; M/F, male/female; pts, patients; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; OS, overall survival; TACE, transarterial chemoembolization; MWA, microwave ablation; NA, not applicable.